Katie Kosko

DocwireNews

Selpercatinib may help prevent or delay the formation of new central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC), specifically those with RET fusions, compared with chemotherapy plus pembrolizumab, according to a recent study published in the Journal of Clinical Oncology.Maurice P&eacute;rol, MD, of the Centre L&eacute;on B&eacute;rard, and colleagues examined CNS scans from LIBRETTO-431, a phase 3 clinical trial that compared first-line selpercatinib with chemotherapy plus&nbsp;pembrolizumab in RET-fusion positive NSCLC.MRI was used to perform intracranial scans for 69% of patients in the selpercatinib arm and 57% of patients in the control arm. At baseline, 150 patients of 192 did not have CNS metastases. Furthermore, there was a lower proportion of patients with baseline CNS metastases in the selpercatinib arm versus the control arm (17.5% v 29.2%, respectively).In the patients without CNS metastases, the 12-month cumulative incidence rate of CNS progression was 1.1% with selpercatinib compared with 14.7% in those in the control arm.&nbsp; Moreover, the 12-month intracranial progression-free survival (PFS) rate was 91.8% in the selpercatinib arm versus 74.7% in the control arm. The hazard ratio for intracranial PFS was .46.Similar trends were observed in the cumulative incidence rate of CNS progression and intracranial PFS in the 42 patients with CNS metastases. The 12-month cumulative incidence rate of CNS progression was 25.7% with selpercatinib compared with 33.3% in the control arm. The 12-month intracranial PFS rate was 63.9% with selpercatinib versus 56.1% with chemotherapy/pembrolizumab.&ldquo;These data supplement the primary LIBRETTO-431 report to further demonstrate that selpercatinib may prevent the formation of new CNS metastases in addition to treating existing CNS metastases,&rdquo; the researchers said.However, several limitations including short follow-up time, small number of events, and low number of evaluable patients in certain subgroups, mean that longer follow-up is required to confirm intracranial efficacy with selpercatinib.This study is of importance because it reinforces how crucial it is to identify RET fusions in first-line patients with NSCLC and subsequently treating them with selpercatinib, the researchers said.Source: <a href="https://ascopubs.org/doi/full/10.1200/JCO.24.00724">Journal of Clinical Oncology</a>

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

LIBRETTO-431 Analysis: Selpercatinib May Have CNS Protective Effect in RET-Fusion Positive NSCLC

Non-Small Cell Lung Cancer

Selpercatinib may help prevent or delay the formation of new central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC).

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe